



Universiteit
Leiden
The Netherlands

GDE transmembrane ecto-enzymes : novel signaling functions through GPI-anchor cleavage

Veen, T.P.M. van

Citation

Veen, T. P. M. van. (2018, September 19). *GDE transmembrane ecto-enzymes : novel signaling functions through GPI-anchor cleavage*. Retrieved from <https://hdl.handle.net/1887/65601>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/65601>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/65601> holds various files of this Leiden University dissertation.

Author: Veen, T.P.M. van

Title: GDE transmembrane ecto-enzymes : novel signaling functions through GPI-anchor cleavage

Issue Date: 2018-09-19



JUNIPERUS

"Battere
la
coccola"

Addendum

References

Nederlandse samenvatting voor leken

Curriculum Vitae

List of Publications

Acknowledgements

References

- Hooke, R., *Micrographia: or Some Physiological Description of Minute Bodies, Made by Magnifying Glasses with Observations and Inquiries Thereupon* J. Martyn and J. Allestry, London, 1665.
- Schwann, T., *Mikroskopische Untersuchungen über die Uebereinstimmung in der Struktur und dem Wachsthum der Thiere und Pflanzen* G. E. Reimer 1839.
- Ferguson, M.A., et al., *Glycosylphosphatidylinositol moiety that anchors Trypanosoma brucei variant surface glycoprotein to the membrane*. Science, 1988. **239**(4841 Pt 1): p. 753-9.
- Low, M.G., *The glycosyl-phosphatidylinositol anchor of membrane proteins*. Biochim Biophys Acta, 1989. **988**(3): p. 427-54.
- Orlean, P. and A.K. Menon, *Thematic review series: lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycosphospholipids*. J Lipid Res, 2007. **48**(5): p. 993-1011.
- Hazenbos, W.L., et al., *Impaired FcεpsilonRI stability, signaling, and effector functions in murine mast cells lacking glycosylphosphatidylinositol-anchored proteins*. Blood, 2011. **118**(16): p. 4377-83.
- Hazenbos, W.L., et al., *Enhanced responses of glycosylphosphatidylinositol anchor-deficient T lymphocytes*. J Immunol, 2004. **173**(6): p. 3810-5.
- Hazenbos, W.L., et al., *GPI-anchor deficiency in myeloid cells causes impaired FcγR effector functions*. Blood, 2004. **104**(9): p. 2825-31.
- Ueda, Y., et al., *PGAP1 knock-out mice show otocephaly and male infertility*. J Biol Chem, 2007. **282**(42): p. 30373-80.
- Nozaki, M., et al., *Developmental abnormalities of glycosylphosphatidylinositol-anchor-deficient embryos revealed by Cre/loxP system*. Lab Invest, 1999. **79**(3): p. 293-9.
- Kawagoe, K., et al., *Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria*. Blood, 1996. **87**(9): p. 3600-6.
- Edvardson, S., et al., *Mutations in the phosphatidylinositol glycan C (PIGC) gene are associated with epilepsy and intellectual disability*. J Med Genet, 2017. **54**(3): p. 196-201.
- Almeida, A.M., et al., *Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency*. Nat Med, 2006. **12**(7): p. 846-51.
- Inoue, N., Y. Murakami, and T. Kinoshita, *Molecular genetics of paroxysmal nocturnal hemoglobinuria*. Int J Hematol, 2003. **77**(2): p. 107-12.
- Zhang, X., et al., *Notum is required for neural and head induction via Wnt deacylation, oxidation, and inactivation*. Dev Cell, 2015. **32**(6): p. 719-30.
- Traister, A., W. Shi, and J. Filmus, *Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface*. Biochem J, 2008. **410**(3): p. 503-11.
- Matas-Rico, E., et al., *Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome*. Cancer Cell, 2016. **30**(6): p. 986.
- Kondoh, G., et al., *Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization*. Nat Med, 2005. **11**(2): p. 160-6.
- Field, M.C., A.K. Menon, and G.A. Cross, *A glycosylphosphatidylinositol protein anchor from procyclic stage Trypanosoma brucei: lipid structure and biosynthesis*. EMBO J, 1991. **10**(10): p. 2731-9.
- Rudd, P.M., et al., *The glycosylation of the complement regulatory protein, human erythrocyte CD59*. J Biol Chem, 1997. **272**(11): p. 7229-44.
- Kinoshita, T., M. Fujita, and Y. Maeda, *Biosynthesis, remodelling and functions of mammalian GPI-anchored proteins: recent progress*. J Biochem, 2008. **144**(3): p. 287-94.

22. Ferguson, M.A.J., T. Kinoshita, and G.W. Hart, *Glycosylphosphatidylinositol Anchors*, in *Essentials of Glycobiology*, A. Varki, et al., Editors. 2009, Cold Spring Harbor Laboratory Press
The Consortium of Glycobiology Editors, La Jolla, California.: Cold Spring Harbor (NY).
23. Butikofer, P., et al., *GPI-anchored proteins: now you see 'em, now you don't*. *Faseb j*, 2001. **15**(2): p. 545-8.
24. McConville, M.J. and M.A. Ferguson, *The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes*. *Biochem J*, 1993. **294** (Pt 2): p. 305-24.
25. Deeg, M.A., et al., *Glycan components in the glycoinositol phospholipid anchor of human erythrocyte acetylcholinesterase. Novel fragments produced by trifluoroacetic acid*. *J Biol Chem*, 1992. **267**(26): p. 18573-80.
26. Redman, C.A., et al., *Structure of the glycosylphosphatidylinositol membrane anchor of human placental alkaline phosphatase*. *Biochem J*, 1994. **302** (Pt 3): p. 861-5.
27. Roberts, W.L., et al., *Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C*. *J Biol Chem*, 1988. **263**(35): p. 18766-75.
28. Roberts, W.L., et al., *Structural characterization of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase by fast atom bombardment mass spectrometry*. *J Biol Chem*, 1988. **263**(35): p. 18776-84.
29. Fujita, M. and T. Kinoshita, *GPI-anchor remodeling: potential functions of GPI-anchors in intracellular trafficking and membrane dynamics*. *Biochim Biophys Acta*, 2012. **1821**(8): p. 1050-8.
30. Mayor, S. and H. Riezman, *Sorting GPI-anchored proteins*. *Nat Rev Mol Cell Biol*, 2004. **5**(2): p. 110-20.
31. Galian, C., et al., *Efficient glycosylphosphatidylinositol (GPI) modification of membrane proteins requires a C-terminal anchoring signal of marginal hydrophobicity*. *J Biol Chem*, 2012. **287**(20): p. 16399-409.
32. Fujita, M. and T. Kinoshita, *Structural remodeling of GPI anchors during biosynthesis and after attachment to proteins*. *FEBS Lett*, 2010. **584**(9): p. 1670-7.
33. Tanaka, S., et al., *Inositol deacylation of glycosylphosphatidylinositol-anchored proteins is mediated by mammalian PGAP1 and yeast Bst1p*. *J Biol Chem*, 2004. **279**(14): p. 14256-63.
34. Fujita, M., et al., *GPI glycan remodeling by PGAP5 regulates transport of GPI-anchored proteins from the ER to the Golgi*. *Cell*, 2009. **139**(2): p. 352-65.
35. Watanabe, H. and G. Kondoh, *Mouse sperm undergo GPI-anchored protein release associated with lipid raft reorganization and acrosome reaction to acquire fertility*. *J Cell Sci*, 2011. **124**(Pt 15): p. 2573-81.
36. Fujita, M., et al., *Sorting of GPI-anchored proteins into ER exit sites by p24 proteins is dependent on remodeled GPI*. *J Cell Biol*, 2011. **194**(1): p. 61-75.
37. Doering, T.L., P.T. Englund, and G.W. Hart, *Detection of glycosphospholipid anchors on proteins*. *Curr Protoc Protein Sci*, 2001. **Chapter 12**: p. Unit 12.5.
38. Strating, J.R. and G.J. Martens, *The p24 family and selective transport processes at the ER-Golgi interface*. *Biol Cell*, 2009. **101**(9): p. 495-509.
39. Strating, J.R., T.G. Hafmans, and G.J. Martens, *Functional diversity among p24 subfamily members*. *Biol Cell*, 2009. **101**(4): p. 207-19.
40. Strating, J.R., T.G. Hafmans, and G.J. Martens, *COP-binding sites in p24delta2 are necessary for proper secretory cargo biosynthesis*. *Int J Biochem Cell Biol*, 2009. **41**(7): p. 1619-27.
41. Castillon, G.A., et al., *The yeast p24 complex regulates GPI-anchored protein transport and quality control by monitoring anchor remodeling*. *Mol Biol Cell*, 2011. **22**(16): p. 2924-36.
42. Paladino, S., et al., *Protein oligomerization modulates raft partitioning and apical sorting of GPI-anchored proteins*. *J Cell Biol*, 2004. **167**(4): p. 699-709.
43. Paladino, S., et al., *Golgi sorting regulates organization and activity of GPI proteins at apical membranes*. *Nat Chem Biol*, 2014. **10**(5): p. 350-7.



44. Suzuki, K.G., et al., *Transient GPI-anchored protein homodimers are units for raft organization and function*. Nat Chem Biol, 2012. **8**(9): p. 774-83.
45. Gowrishankar, K., et al., *Active remodeling of cortical actin regulates spatiotemporal organization of cell surface molecules*. Cell, 2012. **149**(6): p. 1353-67.
46. Goswami, D., et al., *Nanoclusters of GPI-anchored proteins are formed by cortical actin-driven activity*. Cell, 2008. **135**(6): p. 1085-97.
47. Paladino, S., et al., *GPI-anchored proteins are directly targeted to the apical surface in fully polarized MDCK cells*. J Cell Biol, 2006. **172**(7): p. 1023-34.
48. Paladino, S., et al., *Different GPI-attachment signals affect the oligomerisation of GPI-anchored proteins and their apical sorting*. J Cell Sci, 2008. **121**(Pt 24): p. 4001-7.
49. de Hoop, M.J. and C.G. Dotti, *Membrane traffic in polarized neurons in culture*. J Cell Sci Suppl, 1993. **17**: p. 85-92.
50. Brown, D.A. and J.K. Rose, *Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface*. Cell, 1992. **68**(3): p. 533-44.
51. Lipardi, C., L. Nitsch, and C. Zurzolo, *Detergent-insoluble GPI-anchored proteins are apically sorted in fischer rat thyroid cells, but interference with cholesterol or sphingolipids differentially affects detergent insolubility and apical sorting*. Mol Biol Cell, 2000. **11**(2): p. 531-42.
52. Imjeti, N.S., et al., *N-Glycosylation instead of cholesterol mediates oligomerization and apical sorting of GPI-APs in FRT cells*. Mol Biol Cell, 2011. **22**(23): p. 4621-34.
53. Delacour, D., et al., *Apical sorting by galectin-3-dependent glycoprotein clustering*. Traffic, 2007. **8**(4): p. 379-88.
54. Benting, J.H., A.G. Rietveld, and K. Simons, *N-Glycans mediate the apical sorting of a GPI-anchored, raft-associated protein in Madin-Darby canine kidney cells*. J Cell Biol, 1999. **146**(2): p. 313-20.
55. Mayor, S., K.G. Rothberg, and F.R. Maxfield, *Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking*. Science, 1994. **264**(5167): p. 1948-51.
56. Sabharanjak, S., et al., *GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway*. Dev Cell, 2002. **2**(4): p. 411-23.
57. Nichols, B., *Endocytosis of lipid-anchored proteins: excluding GEECs from the crowd*. J Cell Biol, 2009. **186**(4): p. 457-9.
58. Howes, M.T., S. Mayor, and R.G. Parton, *Molecules, mechanisms, and cellular roles of clathrin-independent endocytosis*. Curr Opin Cell Biol, 2010. **22**(4): p. 519-27.
59. Doherty, G.J. and H.T. McMahon, *Mechanisms of endocytosis*. Annu Rev Biochem, 2009. **78**: p. 857-902.
60. Nieznanski, K., et al., *Soluble prion protein inhibits amyloid-beta (A β) fibrillization and toxicity*. J Biol Chem, 2012. **287**(40): p. 33104-8.
61. Skorecki, K.L. and B.I. Freedman, *A suPAR Biomarker for Chronic Kidney Disease*. N Engl J Med, 2015. **373**(20): p. 1971-2.
62. Watanabe, K., et al., *Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for trans activity as a Nodal co-receptor*. J Biol Chem, 2007. **282**(49): p. 35772-86.
63. Barboni, E., et al., *The glycoposphatidylinositol anchor affects the conformation of Thy-1 protein*. J Cell Sci, 1995. **108** (Pt 2): p. 487-97.
64. Titball, R.W., *Bacterial phospholipases C*. Microbiol Rev, 1993. **57**(2): p. 347-66.
65. Metz, C.N., et al., *Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D*. EMBO J, 1994. **13**(7): p. 1741-51.
66. Verghese, G.M., M.F. Gutknecht, and G.H. Caughey, *Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor*. Am J Physiol Cell Physiol, 2006. **291**(6): p. C1258-70.
67. Wilhelm, O.G., et al., *Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression*. J Cell Physiol, 1999. **180**(2): p. 225-35.
68. Ikezawa, H., *Glycosylphosphatidylinositol (GPI)-anchored proteins*. Biol Pharm Bull, 2002. **25**(4): p. 409-17.

69. Low, M.G. and K.S. Huang, *Factors affecting the ability of glycosylphosphatidylinositol-specific phospholipase D to degrade the membrane anchors of cell surface proteins*. *Biochem J*, 1991. **279** (Pt 2): p. 483-93.
70. Kreuger, J., et al., *Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity*. *Dev Cell*, 2004. **7**(4): p. 503-12.
71. Kakugawa, S., et al., *Notum deacylates Wnt proteins to suppress signalling activity*. *Nature*, 2015. **519**(7542): p. 187-92.
72. Kirchhoff, C. and G. Hale, *Cell-to-cell transfer of glycosylphosphatidylinositol-anchored membrane proteins during sperm maturation*. *Mol Hum Reprod*, 1996. **2**(3): p. 177-84.
73. Takayama, T., et al., *Sexually dimorphic expression of the novel germ cell antigen TEX101 during mouse gonad development*. *Biol Reprod*, 2005. **72**(6): p. 1315-23.
74. Fujihara, Y., et al., *Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa*. *Proc Natl Acad Sci U S A*, 2013. **110**(20): p. 8111-6.
75. Yamaguchi, R., et al., *Aberrant distribution of ADAM3 in sperm from both angiotensin-converting enzyme (Ace)- and calmegin (Clgn)-deficient mice*. *Biol Reprod*, 2006. **75**(5): p. 760-6.
76. Leisle, L., et al., *Angiotensin-converting enzyme as a GPlase: a critical reevaluation*. *Nat Med*, 2005. **11**(11): p. 1139-40.
77. Lee, G.H., et al., *A GPI processing phospholipase A2, PGAP6, modulates Nodal signaling in embryos by shedding CRIPTO*. *J Cell Biol*, 2016. **215**(5): p. 705-718.
78. Larson, T.J., M. Ehrmann, and W. Boos, *Periplasmic glycerophosphodiester phosphodiesterase of Escherichia coli, a new enzyme of the glp regulon*. *J Biol Chem*, 1983. **258**(9): p. 5428-32.
79. Larson, T.J. and A.T. van Loo-Bhattacharya, *Purification and characterization of glpQ-encoded glycerophosphodiester phosphodiesterase from Escherichia coli K-12*. *Arch Biochem Biophys*, 1988. **260**(2): p. 577-84.
80. Tommassen, J., et al., *Characterization of two genes, glpQ and ugpQ, encoding glycerophosphoryl diester phosphodiesterases of Escherichia coli*. *Mol Gen Genet*, 1991. **226**(1-2): p. 321-7.
81. Munson, R.S., Jr. and K. Sasaki, *Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesterase*. *J Bacteriol*, 1993. **175**(14): p. 4569-71.
82. Janson, H., et al., *Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures*. *J Infect Dis*, 1999. **180**(3): p. 737-46.
83. Corda, D. and M.A. De Matteis, *Lipid signalling in health and disease*. *FEBS J*, 2013. **280**(24): p. 6280.
84. Forsgren, A., K. Riesbeck, and H. Janson, *Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines*. *Clin Infect Dis*, 2008. **46**(5): p. 726-31.
85. Huu, T.N., et al., *Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial*. *BMC Infect Dis*, 2013. **13**: p. 95.
86. Johnson, R.W., et al., *Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media*. *Vaccine*, 2011. **29**(6): p. 1211-21.
87. Kusser, W. and F. Fiedler, *A novel glycerophosphodiesterase from Bacillus pumilus*. *FEBS Lett*, 1984. **166**(2): p. 301-6.
88. Hadler, K.S., et al., *Structural flexibility enhances the reactivity of the bioremediator glycerophosphodiesterase by fine-tuning its mechanism of hydrolysis*. *J Am Chem Soc*, 2009. **131**(33): p. 11900-8.
89. Yip, S.H., et al., *Directed evolution combined with rational design increases activity of GpdQ toward a non-physiological substrate and alters the oligomeric structure of the enzyme*. *Protein Eng Des Sel*, 2011. **24**(12): p. 861-72.
90. Santelli, E., et al., *Crystal structure of a glycerophosphodiester phosphodiesterase (GDPD) from Thermotoga maritima (TM1621) at 1.60 Å resolution*. *Proteins*, 2004. **56**(1): p. 167-70.

91. Zheng, B., et al., *GDE1/MIR16 is a glycerophosphoinositol phosphodiesterase regulated by stimulation of G protein-coupled receptors*. Proc Natl Acad Sci U S A, 2003. **100**(4): p. 1745-50.
92. Zheng, B., D. Chen, and M.G. Farquhar, *MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16*. Proc Natl Acad Sci U S A, 2000. **97**(8): p. 3999-4004.
93. Bachmann, A.S., F.F. Duennebier, and G. Mocz, *Genomic organization, characterization, and molecular 3D model of GDE1, a novel mammalian glycerophosphoinositol phosphodiesterase*. Gene, 2006. **371**(1): p. 144-53.
94. Kopp, F., et al., *The glycerophospho metabolome and its influence on amino acid homeostasis revealed by brain metabolomics of GDE1(-/-) mice*. Chem Biol, 2010. **17**(8): p. 831-40.
95. Simon, G.M. and B.F. Cravatt, *Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain*. J Biol Chem, 2008. **283**(14): p. 9341-9.
96. Corda, D., et al., *The emerging physiological roles of the glycerophosphodiesterase family*. FEBS J, 2014. **281**(4): p. 998-1016.
97. Yanaka, N., *Mammalian glycerophosphodiester phosphodiesterases*. Biosci Biotechnol Biochem, 2007. **71**(8): p. 1811-8.
98. Okazaki, Y., et al., *A novel glycerophosphodiester phosphodiesterase, GDE5, controls skeletal muscle development via a non-enzymatic mechanism*. J Biol Chem, 2010. **285**(36): p. 27652-63.
99. Corda, D., et al., *The developmentally regulated osteoblast phosphodiesterase GDE3 is glycerophosphoinositol-specific and modulates cell growth*. J Biol Chem, 2009. **284**(37): p. 24848-56.
100. Gallazzini, M., J.D. Ferraris, and M.B. Burg, *GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC*. Proc Natl Acad Sci U S A, 2008. **105**(31): p. 11026-31.
101. Ohshima, N., et al., *New members of the mammalian glycerophosphodiester phosphodiesterase family: GDE4 and GDE7 produce lysophosphatidic acid by lysophospholipase D activity*. J Biol Chem, 2015. **290**(7): p. 4260-71.
102. van Meeteren, L.A., et al., *Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine*. J Biol Chem, 2004. **279**(12): p. 10833-6.
103. Tsuboi, K., et al., *Glycerophosphodiesterase GDE4 as a novel lysophospholipase D: a possible involvement in bioactive N-acyl ethanolamine biosynthesis*. Biochim Biophys Acta, 2015. **1851**(5): p. 537-48.
104. Chang, P.A., et al., *Isolation, characterization and molecular 3D model of human GDE4, a novel membrane protein containing glycerophosphodiester phosphodiesterase domain*. Mol Membr Biol, 2008. **25**(6-7): p. 557-66.
105. Nogusa, Y., et al., *Isolation and characterization of two serpentine membrane proteins containing glycerophosphodiester phosphodiesterase, GDE2 and GDE6*. Gene, 2004. **337**: p. 173-9.
106. Cao, M.D., et al., *Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion*. NMR Biomed, 2016. **29**(8): p. 1098-107.
107. Yanaka, N., et al., *Involvement of membrane protein GDE2 in retinoic acid-induced neurite formation in Neuro2A cells*. FEBS Lett, 2007. **581**(4): p. 712-8.
108. Rao, M. and S. Sockanathan, *Transmembrane protein GDE2 induces motor neuron differentiation in vivo*. Science, 2005. **309**(5744): p. 2212-5.
109. Sabharwal, P., et al., *GDE2 regulates subtype-specific motor neuron generation through inhibition of Notch signaling*. Neuron, 2011. **71**(6): p. 1058-70.
110. Park, S., et al., *GDE2 promotes neurogenesis by glycosylphosphatidylinositol-anchor cleavage of RECK*. Science, 2013. **339**(6117): p. 324-8.
111. Muraguchi, T., et al., *RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity*. Nat Neurosci, 2007. **10**(7): p. 838-45.

112. van Ree, J.W., *Changing world, changing doctors, changing education!* Sante Publique, 2003. **15 Spec No**: p. 151-5.
113. Cave, C., et al., *GDE2 is essential for neuronal survival in the postnatal mammalian spinal cord*. Mol Neurodegener, 2017. **12**(1): p. 8.
114. Sudo, H., et al., *In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria*. J Cell Biol, 1983. **96**(1): p. 191-8.
115. Yanaka, N., et al., *Novel membrane protein containing glycerophosphodiester phosphodiesterase motif is transiently expressed during osteoblast differentiation*. J Biol Chem, 2003. **278**(44): p. 43595-602.
116. van Veen, M., et al., *Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells*. Elife, 2017. **6**.
117. Periz, G., et al., *GDP-bound Galphai2 regulates spinal motor neuron differentiation through interaction with GDE2*. Dev Biol, 2010. **341**(1): p. 213-21.
118. Yan, Y., et al., *The antioxidant enzyme Prdx1 controls neuronal differentiation by thiol-redox-dependent activation of GDE2*. Cell, 2009. **138**(6): p. 1209-21.
119. Yan, Y., et al., *Prdx4 is a compartment-specific H2O2 sensor that regulates neurogenesis by controlling surface expression of GDE2*. Nat Commun, 2015. **6**: p. 7006.
120. Smith, H.W. and C.J. Marshall, *Regulation of cell signalling by uPAR*. Nat Rev Mol Cell Biol, 2010. **11**(1): p. 23-36.
121. Ferraris, G.M. and N. Sidenius, *Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction*. Semin Thromb Hemost, 2013. **39**(4): p. 347-55.
122. Boonstra, M.C., et al., *Clinical applications of the urokinase receptor (uPAR) for cancer patients*. Curr Pharm Des, 2011. **17**(19): p. 1890-910.
123. Madsen, C.D., et al., *uPAR-induced cell adhesion and migration: vitronectin provides the key*. J Cell Biol, 2007. **177**(5): p. 927-39.
124. Ferraris, G.M., et al., *The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins*. EMBO J, 2014. **33**(21): p. 2458-72.
125. Persson, M., et al., *First-in-human uPAR PET: Imaging of Cancer Aggressiveness*. Theranostics, 2015. **5**(12): p. 1303-16.
126. Ploug, M., et al., *A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria*. Eur J Biochem, 1992. **208**(2): p. 397-404.
127. Pedersen, N., et al., *A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer*. J Clin Invest, 1993. **92**(5): p. 2160-7.
128. Haupt, T.H., et al., *Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study*. Crit Care, 2012. **16**(4): p. R130.
129. Sidenius, N., et al., *Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection*. Blood, 2000. **96**(13): p. 4091-5.
130. Hayek, S.S., A.A. Quyyumi, and J. Reiser, *Soluble Urokinase Receptor and Chronic Kidney Disease*. N Engl J Med, 2016. **374**(9): p. 891.
131. Stephens, R.W., et al., *Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis*. J Natl Cancer Inst, 1999. **91**(10): p. 869-74.
132. Shariat, S.F., et al., *Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis*. J Clin Oncol, 2007. **25**(4): p. 349-55.
133. Mustjoki, S., et al., *Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy*. Cancer Res, 2000. **60**(24): p. 7126-32.
134. Montuori, N. and P. Ragno, *Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR*. Front Biosci (Landmark Ed), 2009. **14**: p. 2494-503.
135. Scallion, B.J., et al., *Primary structure and functional activity of a phosphatidylinositol-glycan-specific phospholipase D*. Science, 1991. **252**(5004): p. 446-8.

136. Mann, K.J., et al., *Effect of glycosylphosphatidylinositol (GPI)-phospholipase D overexpression on GPI metabolism*. *Biochem J*, 2004. **378**(Pt 2): p. 641-8.
137. Matas-Rico, E., et al., *Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome*. *Cancer Cell*, 2016. **30**(4): p. 548-562.
138. Matas-Rico, E., M. van Veen, and W.H. Moolenaar, *Neuronal differentiation through GPI-anchor cleavage* *Cell Cycle*, 2016. **in press**.
139. Maeda, Y. and T. Kinoshita, *Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins*. *Prog Lipid Res*, 2011. **50**(4): p. 411-24.
140. Cunningham, O., et al., *Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions*. *EMBO J*, 2003. **22**(22): p. 5994-6003.
141. Yang, J., et al., *The I-TASSER Suite: protein structure and function prediction*. *Nat Methods*, 2015. **12**(1): p. 7-8.
142. Kjoller, L. and A. Hall, *Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin*. *J Cell Biol*, 2001. **152**(6): p. 1145-57.
143. LeBeau, A.M., et al., *Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer*. *Cancer Res*, 2013. **73**(7): p. 2070-81.
144. Barretina, J., et al., *The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity*. *Nature*, 2012. **483**(7391): p. 603-7.
145. Hoyer-Hansen, G., et al., *Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain*. *J Biol Chem*, 1992. **267**(25): p. 18224-9.
146. Paulick, M.G. and C.R. Bertozzi, *The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins*. *Biochemistry*, 2008. **47**(27): p. 6991-7000.
147. Kinoshita, T. and M. Fujita, *Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling*. *J Lipid Res*, 2016. **57**(1): p. 6-24.
148. Furlan, F., et al., *Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function*. *J Bone Miner Res*, 2007. **22**(9): p. 1387-96.
149. Munch, E.M., et al., *Differentially expressed genes in preimplantation human embryos: potential candidate genes for blastocyst formation and implantation*. *J Assist Reprod Genet*, 2016. **33**(8): p. 1017-25.
150. Pierleoni, C., et al., *Immunohistochemical identification of the receptor for urokinase plasminogen activator associated with fibrin deposition in normal and ectopic human placenta*. *Placenta*, 1998. **19**(7): p. 501-8.
151. Mulhaupt, H.A., et al., *Expression of urokinase receptors by human trophoblast. A histochemical and ultrastructural analysis*. *Lab Invest*, 1994. **71**(3): p. 392-400.
152. Zhao, B., et al., *Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography*. *Data Brief*, 2015. **5**: p. 107-13.
153. Caiolfa, V.R., et al., *Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies*. *J Cell Biol*, 2007. **179**(5): p. 1067-82.
154. Cong, L., et al., *Multiplex genome engineering using CRISPR/Cas systems*. *Science*, 2013. **339**(6121): p. 819-23.
155. Blomen, V.A., et al., *Gene essentiality and synthetic lethality in haploid human cells*. *Science*, 2015. **350**(6264): p. 1092-6.
156. Mehlert, A. and M.A. Ferguson, *Proteomic scale high-sensitivity analyses of GPI membrane anchors*. *Glycoconj J*, 2009. **26**(8): p. 915-21.
157. Doering, T.L., P.T. Englund, and G.W. Hart, *Detection of glycosphospholipid anchors on proteins*. *Curr Protoc Protein Sci*, 2001. **Chapter 12**: p. Unit 12 5.
158. Brinkman, E.K., et al., *Easy quantitative assessment of genome editing by sequence trace decomposition*. *Nucleic Acids Res*, 2014. **42**(22): p. e168.

159. Jiang, M., J. Stanke, and J.M. Lahti, *The connections between neural crest development and neuroblastoma*. *Curr Top Dev Biol*, 2011. **94**: p. 77-127.
160. Louis, C.U. and J.M. Shohet, *Neuroblastoma: molecular pathogenesis and therapy*. *Annu Rev Med*, 2015. **66**: p. 49-63.
161. Maris, J.M., *Recent advances in neuroblastoma*. *N Engl J Med*, 2010. **362**(23): p. 2202-11.
162. Brodeur, G.M. and R. Bagatell, *Mechanisms of neuroblastoma regression*. *Nat Rev Clin Oncol*, 2014. **11**(12): p. 704-13.
163. Molenaar, J.J., et al., *Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes*. *Nature*, 2012. **483**(7391): p. 589-93.
164. Pugh, T.J., et al., *The genetic landscape of high-risk neuroblastoma*. *Nat Genet*, 2013. **45**(3): p. 279-84.
165. van Nes, J., et al., *A NOTCH3 transcriptional module induces cell motility in neuroblastoma*. *Clin Cancer Res*, 2013. **19**(13): p. 3485-94.
166. Matthay, K.K., et al., *Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study*. *J Clin Oncol*, 2009. **27**(7): p. 1007-13.
167. Ganeshan, V.R. and N.F. Schor, *Pharmacologic management of high-risk neuroblastoma in children*. *Paediatr Drugs*, 2011. **13**(4): p. 245-55.
168. Holzel, M., et al., *NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome*. *Cell*, 2010. **142**(2): p. 218-29.
169. Brodeur, G.M., et al., *Therapeutic targets for neuroblastomas*. *Expert Opin Ther Targets*, 2014. **18**(3): p. 277-92.
170. Brodeur, G.M., *Neuroblastoma: biological insights into a clinical enigma*. *Nat Rev Cancer*, 2003. **3**(3): p. 203-16.
171. Welz, T., J. Wellbourne-Wood, and E. Kerkhoff, *Orchestration of cell surface proteins by Rab11*. *Trends Cell Biol*, 2014. **24**(7): p. 407-15.
172. Grant, B.D. and J.G. Donaldson, *Pathways and mechanisms of endocytic recycling*. *Nat Rev Mol Cell Biol*, 2009. **10**(9): p. 597-608.
173. Ridley, A.J., *Rho GTPase signalling in cell migration*. *Curr Opin Cell Biol*, 2015. **36**: p. 103-112.
174. Hall, A. and G. Lalli, *Rho and Ras GTPases in axon growth, guidance, and branching*. *Cold Spring Harb Perspect Biol*, 2010. **2**(2): p. a001818.
175. Govek, E.E., S.E. Newey, and L. Van Aelst, *The role of the Rho GTPases in neuronal development*. *Genes Dev*, 2005. **19**(1): p. 1-49.
176. Hall, A., *Rho family GTPases*. *Biochem Soc Trans*, 2012. **40**(6): p. 1378-82.
177. Spuul, P., et al., *Importance of RhoGTPases in formation, characteristics, and functions of invadosomes*. *Small GTPases*, 2014. **5**: p. e28195.
178. Hirose, M., et al., *Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells*. *J Cell Biol*, 1998. **141**(7): p. 1625-36.
179. Kranenburg, O., et al., *Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction*. *Mol Biol Cell*, 1999. **10**(6): p. 1851-7.
180. Moolenaar, W.H., *Lysophosphatidic acid, a multifunctional phospholipid messenger*. *J Biol Chem*, 1995. **270**(22): p. 12949-52.
181. Frisca, F., et al., *Rho/ROCK pathway is essential to the expansion, differentiation, and morphological rearrangements of human neural stem/progenitor cells induced by lysophosphatidic acid*. *J Lipid Res*, 2013. **54**(5): p. 1192-206.
182. Jalink, K., et al., *Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho*. *J Cell Biol*, 1994. **126**(3): p. 801-10.
183. Leeuwen, F.N., et al., *The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho*. *J Cell Biol*, 1997. **139**(3): p. 797-807.
184. Sander, E.E., et al., *Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior*. *J Cell Biol*, 1999. **147**(5): p. 1009-22.



185. Guilluy, C., R. Garcia-Mata, and K. Burridge, *Rho protein crosstalk: another social network?* Trends Cell Biol, 2011. **21**(12): p. 718-26.
186. Nakamura, F., *FilGAP and its close relatives: a mediator of Rho-Rac antagonism that regulates cell morphology and migration.* Biochem J, 2013. **453**(1): p. 17-25.
187. Kedziora, K.M., et al., *Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.* J Biol Chem, 2016. **291**(9): p. 4323-33.
188. Filmus, J., M. Capurro, and J. Rast, *Glypicans.* Genome Biol, 2008. **9**(5): p. 224.
189. Allen, N.J., et al., *Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors.* Nature, 2012. **486**(7403): p. 410-4.
190. Veugeliers, M., et al., *Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans.* J Biol Chem, 1999. **274**(38): p. 26968-77.
191. Filmus, J. and M. Capurro, *Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.* FEBS J, 2013. **280**(10): p. 2471-6.
192. Han, S., et al., *Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer.* Oncotarget, 2016.
193. Peters, M.G., et al., *Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model.* Breast Cancer Res Treat, 2003. **80**(2): p. 221-32.
194. Raghupathy, R., et al., *Transbilayer lipid interactions mediate nanoclustering of lipid-anchored proteins.* Cell, 2015. **161**(3): p. 581-594.
195. Filmus, J. and M. Capurro, *The role of glypicans in Hedgehog signaling.* Matrix Biol, 2014. **35**: p. 248-52.
196. Capurro, M.I., et al., *Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.* Cancer Res, 2005. **65**(14): p. 6245-54.
197. Yiu, G.K., et al., *NFAT promotes carcinoma invasive migration through glypican-6.* Biochem J, 2011. **440**(1): p. 157-66.
198. Capurro, M., et al., *Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.* J Cell Sci, 2014. **127**(Pt 7): p. 1565-75.
199. Coles, C.H., E.Y. Jones, and A.R. Aricescu, *Extracellular regulation of type IIa receptor protein tyrosine phosphatases: mechanistic insights from structural analyses.* Semin Cell Dev Biol, 2015. **37**: p. 98-107.
200. Coles, C.H., et al., *Proteoglycan-specific molecular switch for RPTPsigma clustering and neuronal extension.* Science, 2011. **332**(6028): p. 484-8.
201. Chagnon, M.J., et al., *Receptor tyrosine phosphatase sigma (RPTPsigma) regulates, p250GAP, a novel substrate that attenuates Rac signaling.* Cell Signal, 2010. **22**(11): p. 1626-33.
202. Novitsch, B.G. and S.J. Butler, *Reducing the mystery of neuronal differentiation.* Cell, 2009. **138**(6): p. 1062-4.
203. Topanurak, S., et al., *High NaCl- and urea-induced posttranslational modifications that increase glycerophosphocholine by inhibiting GPD5 phosphodiesterase.* Proc Natl Acad Sci U S A, 2013. **110**(18): p. 7482-7.
204. Bewick, V., L. Cheek, and J. Ball, *Statistics review 12: survival analysis.* Crit Care, 2004. **8**(5): p. 389-94.
205. Slaymaker, I.M., et al., *Rationally engineered Cas9 nucleases with improved specificity.* Science, 2016. **351**(6268): p. 84-8.
206. Folling, J., et al., *Fluorescence nanoscopy by ground-state depletion and single-molecule return.* Nat Methods, 2008. **5**(11): p. 943-5.
207. Hoogendoorn, E., et al., *The fidelity of stochastic single-molecule super-resolution reconstructions critically depends upon robust background estimation.* Sci Rep, 2014. **4**: p. 3854.
208. Price, L.S., et al., *Activation of Rac and Cdc42 by integrins mediates cell spreading.* Mol Biol Cell, 1998. **9**(7): p. 1863-71.
209. Trapnell, C., L. Pachter, and S.L. Salzberg, *TopHat: discovering splice junctions with RNA-Seq.* Bioinformatics, 2009. **25**(9): p. 1105-11.
210. Anders, S., P.T. Pyl, and W. Huber, *HTSeq--a Python framework to work with high-throughput sequencing data.* Bioinformatics, 2015. **31**(2): p. 166-9.
211. Law, C.W., et al., *voom: Precision weights unlock linear model analysis tools for RNA-seq read counts.* Genome Biol, 2014. **15**(2): p. R29.

212. Krawitz, P.M., et al., *Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome*. Nat Genet, 2010. **42**(10): p. 827-9.
213. Krawitz, P.M., et al., *Mutations in PIGO, a member of the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation*. Am J Hum Genet, 2012. **91**(1): p. 146-51.
214. Bosse, K.R. and J.M. Maris, *Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations*. Cancer, 2016. **122**(1): p. 20-33.
215. Hayashi, Y., et al., *Glypicans regulate JAK/STAT signaling and distribution of the Unpaired morphogen*. Development, 2012. **139**(22): p. 4162-71.
216. Jen, Y.H., M. Musacchio, and A.D. Lander, *Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis*. Neural Dev, 2009. **4**: p. 33.
217. O'Callaghan, P., et al., *Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells*. Brain Pathol, 2008. **18**(4): p. 548-61.
218. van Horssen, J., et al., *Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains*. Acta Neuropathol, 2001. **102**(6): p. 604-14.
219. Dwivedi, P.P., N. Lam, and B.C. Powell, *Boning up on glypicans--opportunities for new insights into bone biology*. Cell Biochem Funct, 2013. **31**(2): p. 91-114.
220. de Wit, J., et al., *Unbiased discovery of glypican as a receptor for LRRTM4 in regulating excitatory synapse development*. Neuron, 2013. **79**(4): p. 696-711.
221. Ko, J.S., et al., *PTPsigma functions as a presynaptic receptor for the glypican-4/LRRTM4 complex and is essential for excitatory synaptic transmission*. Proc Natl Acad Sci U S A, 2015. **112**(6): p. 1874-9.
222. Farhy-Tselnicker, I., et al., *Astrocyte-Secreted Glypican 4 Regulates Release of Neuronal Pentraxin 1 from Axons to Induce Functional Synapse Formation*. Neuron, 2017. **96**(2): p. 428-445 e13.
223. Horn, K.E., et al., *Receptor protein tyrosine phosphatase sigma regulates synapse structure, function and plasticity*. J Neurochem, 2012. **122**(1): p. 147-61.
224. Dagdanova, A., et al., *Characterization of the prion protein in human urine*. J Biol Chem, 2010. **285**(40): p. 30489-95.
225. Chesebro, B., et al., *Anchorless prion protein results in infectious amyloid disease without clinical scrapie*. Science, 2005. **308**(5727): p. 1435-9.
226. Wykosky, J., et al., *Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor*. Oncogene, 2008. **27**(58): p. 7260-73.
227. Egea, J. and R. Klein, *Bidirectional Eph-ephrin signaling during axon guidance*. Trends Cell Biol, 2007. **17**(5): p. 230-8.
228. Cramer, K.S. and I.J. Miko, *Eph-ephrin signaling in nervous system development*. F1000Res, 2016. **5**.
229. Stockli, K.A., et al., *Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain*. J Cell Biol, 1991. **115**(2): p. 447-59.
230. Masu, Y., et al., *Disruption of the CNTF gene results in motor neuron degeneration*. Nature, 1993. **365**(6441): p. 27-32.
231. Dutta, R., et al., *Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients*. Brain, 2007. **130**(Pt 10): p. 2566-76.
232. Davis, S., et al., *Released form of CNTF receptor alpha component as a soluble mediator of CNTF responses*. Science, 1993. **259**(5102): p. 1736-9.
233. Lin, H.W., et al., *Ciliary neurotrophic factor (CNTF) plus soluble CNTF receptor alpha increases cyclooxygenase-2 expression, PGE2 release and interferon-gamma-induced CD40 in murine microglia*. J Neuroinflammation, 2009. **6**: p. 7.
234. He, W., et al., *Membrane distal cytokine binding domain of LIFR interacts with soluble CNTFR in vitro*. FEBS Lett, 2002. **514**(2-3): p. 214-8.
235. Hase, A., et al., *Characterization of glial cell line-derived neurotrophic factor family receptor alpha-1 in peripheral nerve Schwann cells*. J Neurochem, 2005. **95**(2): p. 537-43.

236. Peterziel, H., K. Unsicker, and K. Kriegelstein, *TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane*. J Cell Biol, 2002. **159**(1): p. 157-67.
237. Compton, A.G., et al., *Mutations in contactin-1, a neural adhesion and neuromuscular junction protein, cause a familial form of lethal congenital myopathy*. Am J Hum Genet, 2008. **83**(6): p. 714-24.
238. Gennarini, G., et al., *Transfected F3/F11 neuronal cell surface protein mediates intercellular adhesion and promotes neurite outgrowth*. Neuron, 1991. **6**(4): p. 595-606.
239. Durbec, P., et al., *A soluble form of the F3 neuronal cell adhesion molecule promotes neurite outgrowth*. J Cell Biol, 1992. **117**(4): p. 877-87.
240. Lamprianou, S., et al., *A complex between contactin-1 and the protein tyrosine phosphatase PTPRZ controls the development of oligodendrocyte precursor cells*. Proc Natl Acad Sci U S A, 2011. **108**(42): p. 17498-503.
241. Ninov, N., M. Borius, and D.Y. Stainier, *Different levels of Notch signaling regulate quiescence, renewal and differentiation in pancreatic endocrine progenitors*. Development, 2012. **139**(9): p. 1557-67.
242. Tehrani, Z. and S. Lin, *Endocrine pancreas development in zebrafish*. Cell Cycle, 2011. **10**(20): p. 3466-72.
243. Wang, Z., et al., *Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy*. Anticancer Res, 2011. **31**(4): p. 1105-13.
244. Zecchin, E., et al., *Distinct delta and jagged genes control sequential segregation of pancreatic cell types from precursor pools in zebrafish*. Dev Biol, 2007. **301**(1): p. 192-204.
245. Apelqvist, A., et al., *Notch signalling controls pancreatic cell differentiation*. Nature, 1999. **400**(6747): p. 877-81.
246. Esni, F., et al., *Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas*. Development, 2004. **131**(17): p. 4213-24.
247. Matas-Rico, E., M. van Veen, and W.H. Moolenaar, *Neuronal differentiation through GPI-anchor cleavage*. Cell Cycle, 2016: p. 1-2.
248. Nasevicius, A. and S.C. Ekker, *Effective targeted gene 'knockdown' in zebrafish*. Nat Genet, 2000. **26**(2): p. 216-20.
249. Field, H.A., et al., *Formation of the digestive system in zebrafish. II. Pancreas morphogenesis*. Dev Biol, 2003. **261**(1): p. 197-208.
250. Appel, B., et al., *Motoneuron fate specification revealed by patterned LIM homeobox gene expression in embryonic zebrafish*. Development, 1995. **121**(12): p. 4117-25.
251. Dasen, J.S. and T.M. Jessell, *Hox networks and the origins of motor neuron diversity*. Curr Top Dev Biol, 2009. **88**: p. 169-200.
252. Uhlen, M., et al., *Proteomics. Tissue-based map of the human proteome*. Science, 2015. **347**(6220): p. 1260419.
253. Lang, Q., et al., *Cloning and characterization of a human GDPD domain-containing protein GDPD5*. Mol Biol Rep, 2008. **35**(3): p. 351-9.
254. Gupta, M. and M. Brand, *Identification and expression analysis of zebrafish glypicans during embryonic development*. PLoS One, 2013. **8**(11): p. e80824.
255. Strate, I., F. Tessadori, and J. Bakkens, *Glypican4 promotes cardiac specification and differentiation by attenuating canonical Wnt and Bmp signaling*. Development, 2015. **142**(10): p. 1767-76.
256. High, F.A. and J.A. Epstein, *The multifaceted role of Notch in cardiac development and disease*. Nat Rev Genet, 2008. **9**(1): p. 49-61.
257. Zhao, L., et al., *Notch signaling regulates cardiomyocyte proliferation during zebrafish heart regeneration*. Proc Natl Acad Sci U S A, 2014. **111**(4): p. 1403-8.
258. Kimmel, C.B., et al., *Stages of embryonic development of the zebrafish*. Dev Dyn, 1995. **203**(3): p. 253-310.
259. Thisse, C. and B. Thisse, *High-resolution in situ hybridization to whole-mount zebrafish embryos*. Nat Protoc, 2008. **3**(1): p. 59-69.
260. Zhang, Y., U. Werling, and W. Edelmann, *Seamless Ligation Cloning Extract (SLiCE) cloning method*. Methods Mol Biol, 2014. **1116**: p. 235-44.
261. Bessler, M., A. Schaefer, and P. Keller, *Paroxysmal nocturnal hemoglobinuria: insights from recent advances in molecular biology*. Transfus Med Rev, 2001. **15**(4): p. 255-67.

262. Takeda, J., et al., *Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria*. *Cell*, 1993. **73**(4): p. 703-11.
263. Sharom, F.J. and G. Radeva, *GPI-anchored protein cleavage in the regulation of transmembrane signals*. *Subcell Biochem*, 2004. **37**: p. 285-315.
264. Kakugawa, S., et al., *Notum deacylates Wnt proteins to suppress signalling activity*. *Nature*, 2015. **519**(7542): p. 187-192.
265. Muller, A., et al., *Selective and programmed cleavage of GPI-anchored proteins from the surface membrane by phospholipase C*. *Biochim Biophys Acta*, 2012. **1818**(1): p. 117-24.
266. Cortes, L.K., et al., *Proteomic identification of mammalian cell surface derived glycosylphosphatidylinositol-anchored proteins through selective glycan enrichment*. *Proteomics*, 2014. **14**(21-22): p. 2471-84.
267. Nicholson, T.B. and C.P. Stanners, *Specific inhibition of GPI-anchored protein function by homing and self-association of specific GPI anchors*. *J Cell Biol*, 2006. **175**(4): p. 647-59.
268. Saha, S., A.A. Anilkumar, and S. Mayor, *GPI-anchored protein organization and dynamics at the cell surface*. *J Lipid Res*, 2016. **57**(2): p. 159-75.
269. Barbieri, E., P.P. Di Fiore, and S. Sigismund, *Endocytic control of signaling at the plasma membrane*. *Curr Opin Cell Biol*, 2016. **39**: p. 21-7.
270. Irannejad, R., et al., *Effects of endocytosis on receptor-mediated signaling*. *Curr Opin Cell Biol*, 2015. **35**: p. 137-43.
271. Simons, K. and G. van Meer, *Lipid sorting in epithelial cells*. *Biochemistry*, 1988. **27**(17): p. 6197-202.
272. Simons, K. and E. Ikonen, *Functional rafts in cell membranes*. *Nature*, 1997. **387**(6633): p. 569-72.
273. Edidin, M., *The state of lipid rafts: from model membranes to cells*. *Annu Rev Biophys Biomol Struct*, 2003. **32**: p. 257-83.
274. Simons, K. and W.L. Vaz, *Model systems, lipid rafts, and cell membranes*. *Annu Rev Biophys Biomol Struct*, 2004. **33**: p. 269-95.
275. Mayor, S. and F.R. Maxfield, *Insolubility and redistribution of GPI-anchored proteins at the cell surface after detergent treatment*. *Mol Biol Cell*, 1995. **6**(7): p. 929-44.
276. Heerklotz, H., *Triton promotes domain formation in lipid raft mixtures*. *Biophys J*, 2002. **83**(5): p. 2693-701.
277. van Zanten, T.S., et al., *Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion*. *Proc Natl Acad Sci U S A*, 2009. **106**(44): p. 18557-62.
278. Zhang, F., et al., *Lateral diffusion of membrane-spanning and glycosylphosphatidylinositol-linked proteins: toward establishing rules governing the lateral mobility of membrane proteins*. *J Cell Biol*, 1991. **115**(1): p. 75-84.
279. Dietrich, C., et al., *Relationship of lipid rafts to transient confinement zones detected by single particle tracking*. *Biophys J*, 2002. **82**(1 Pt 1): p. 274-84.
280. Kusumi, A., et al., *Paradigm shift of the plasma membrane concept from the two-dimensional continuum fluid to the partitioned fluid: high-speed single-molecule tracking of membrane molecules*. *Annu Rev Biophys Biomol Struct*, 2005. **34**: p. 351-78.
281. Lenne, P.F., et al., *Dynamic molecular confinement in the plasma membrane by microdomains and the cytoskeleton meshwork*. *EMBO J*, 2006. **25**(14): p. 3245-56.
282. Chiantia, S. and E. London, *Acyl chain length and saturation modulate interleaflet coupling in asymmetric bilayers: effects on dynamics and structural order*. *Biophys J*, 2012. **103**(11): p. 2311-9.
283. Polley, A., S. Mayor, and M. Rao, *Bilayer registry in a multicomponent asymmetric membrane: dependence on lipid composition and chain length*. *J Chem Phys*, 2014. **141**(6): p. 064903.
284. Rao, M. and S. Mayor, *Active organization of membrane constituents in living cells*. *Curr Opin Cell Biol*, 2014. **29**: p. 126-32.
285. Legler, D.F., et al., *Differential insertion of GPI-anchored GFPs into lipid rafts of live cells*. *FASEB J*, 2005. **19**(1): p. 73-5.
286. Gordon, V.M., et al., *Clostridium septicum alpha toxin uses glycosylphosphatidylinositol-anchored protein receptors*. *J Biol Chem*, 1999. **274**(38): p. 27274-80.
287. Dolezal, S., et al., *Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by C. septicum alpha toxin*. *Cancer Biomark*, 2014. **14**(1): p. 55-62.



288. Parkin, E.T., et al., *Dual mechanisms for shedding of the cellular prion protein*. J Biol Chem, 2004. **279**(12): p. 11170-8.
289. Ieguchi, K., et al., *ADAM12-cleaved ephrin-A1 contributes to lung metastasis*. Oncogene, 2014. **33**(17): p. 2179-90.
290. Taylor, D.R., et al., *Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein*. J Biol Chem, 2009. **284**(34): p. 22590-600.
291. Mann, K.J. and D. Seveler, *1,10-Phenanthroline inhibits glycosylphosphatidylinositol anchoring by preventing phosphoethanolamine addition to glycosylphosphatidylinositol anchor precursors*. Biochemistry, 2001. **40**(5): p. 1205-13.
292. Seveler, D., K.J. Mann, and M.E. Medof, *Differential effect of 1,10-phenanthroline on mammalian, yeast, and parasite glycosylphosphatidylinositol anchor synthesis*. Biochem Biophys Res Commun, 2001. **288**(5): p. 1112-8.
293. Huang, J., et al., *A sandwich ELISA for detection of soluble GPI-80, a glycosylphosphatidyl-inositol (GPI)-anchored protein on human leukocytes involved in regulation of neutrophil adherence and migration--its release from activated neutrophils and presence in synovial fluid of rheumatoid arthritis patients*. Microbiol Immunol, 2001. **45**(6): p. 467-71.
294. Piec, G. and M. Le Hir, *The soluble 'low-Km' 5'-nucleotidase of rat kidney represents solubilized ecto-5'-nucleotidase*. Biochem J, 1991. **273**(Pt 2): p. 409-13.
295. Vogel, M., et al., *Soluble low-Km 5'-nucleotidase from electric-ray (Torpedo marmorata) electric organ and bovine cerebral cortex is derived from the glycosyl-phosphatidylinositol-anchored ectoenzyme by phospholipase C cleavage*. Biochem J, 1992. **284** (Pt 3): p. 621-4.
296. Park, S.W., et al., *Endogenous glycosylphosphatidylinositol-specific phospholipase C releases renal dipeptidase from kidney proximal tubules in vitro*. Biochem J, 2001. **353**(Pt 2): p. 339-44.
297. Almqvist, P. and S.R. Carlsson, *Characterization of a hydrophilic form of Thy-1 purified from human cerebrospinal fluid*. J Biol Chem, 1988. **263**(25): p. 12709-15.
298. Movahedi, S. and N.M. Hooper, *Insulin stimulates the release of the glycosyl phosphatidylinositol-anchored membrane dipeptidase from 3T3-L1 adipocytes through the action of a phospholipase C*. Biochem J, 1997. **326** (Pt 2): p. 531-7.
299. Park, S.W., et al., *Spontaneous release of glycosylphosphatidylinositol (GPI)-anchored renal dipeptidase from porcine renal proximal tubules*. Arch Pharm Res, 2002. **25**(1): p. 80-5.
300. Elortza, F., et al., *Modification-specific proteomics of plasma membrane proteins: identification and characterization of glycosylphosphatidylinositol-anchored proteins released upon phospholipase D treatment*. J Proteome Res, 2006. **5**(4): p. 935-43.
301. Ueda, Y., et al., *Regulation of the transbilayer movement of diacylglycerol in the plasma membrane*. Biochimie, 2014. **107 Pt A**: p. 43-50.
302. Creaney, J., I.M. Dick, and B.W. Robinson, *Discovery of new biomarkers for malignant mesothelioma*. Curr Pulmonol Rep, 2015. **4**(1): p. 15-21.
303. Wu, G., et al., *Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer*. Cancer Res, 2006. **66**(20): p. 9829-36.
304. Jiang, W.W., et al., *Alterations of GPI transamidase subunits in head and neck squamous carcinoma*. Mol Cancer, 2007. **6**: p. 74.
305. Nagpal, J.K., et al., *Profiling the expression pattern of GPI transamidase complex subunits in human cancer*. Mod Pathol, 2008. **21**(8): p. 979-91.
306. Zhao, P., et al., *Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in breast carcinoma*. J Biol Chem, 2012. **287**(30): p. 25230-40.
307. Dangaj, D., et al., *Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody*. PLoS One, 2011. **6**(12): p. e28386.

308. Huber, M.C., et al., *uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R*. BMC Cancer, 2016. **16**: p. 615.
309. Sidenius, N., C.F. Sier, and F. Blasi, *Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo*. FEBS Lett, 2000. **475**(1): p. 52-6.
310. Grisaru, S., et al., *Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis*. Dev Biol, 2001. **231**(1): p. 31-46.
311. Paine-Saunders, S., et al., *glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development*. Dev Biol, 2000. **225**(1): p. 179-87.
312. Song, H.H., et al., *The loss of glypican-3 induces alterations in Wnt signaling*. J Biol Chem, 2005. **280**(3): p. 2116-25.
313. Pilia, G., et al., *Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome*. Nat Genet, 1996. **12**(3): p. 241-7.
314. Veugelers, M., et al., *GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome*. Genomics, 1998. **53**(1): p. 1-11.
315. Filmus, J., *Glypicans in growth control and cancer*. Glycobiology, 2001. **11**(3): p. 19R-23R.
316. Shirakawa, H., et al., *Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer*. Int J Oncol, 2009. **34**(3): p. 649-56.
317. Kirkpatrick, C.A., et al., *Spatial regulation of Wntless morphogen distribution and signaling by Dally-like protein*. Dev Cell, 2004. **7**(4): p. 513-23.
318. Franch-Marro, X., et al., *Glypicans shunt the Wntless signal between local signalling and further transport*. Development, 2005. **132**(4): p. 659-66.
319. Nybakken, K. and N. Perrimon, *Heparan sulfate proteoglycan modulation of developmental signaling in Drosophila*. Biochim Biophys Acta, 2002. **1573**(3): p. 280-91.
320. Fico, A., F. Maina, and R. Dono, *Fine-tuning of cell signaling by glypicans*. Cell Mol Life Sci, 2011. **68**(6): p. 923-9.
321. Capurro, M., et al., *Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling*. J Cell Biol, 2017. **216**(9): p. 2911-2926.
322. Chen, Y., et al., *Retinoic acid signaling is essential for pancreas development and promotes endocrine at the expense of exocrine cell differentiation in Xenopus*. Dev Biol, 2004. **271**(1): p. 144-60.
323. Huang, W., et al., *Retinoic acid plays an evolutionarily conserved and biphasic role in pancreas development*. Dev Biol, 2014. **394**(1): p. 83-93.
324. Zertal-Zidani, S., A. Bounacer, and R. Scharfmann, *Regulation of pancreatic endocrine cell differentiation by sulphated proteoglycans*. Diabetologia, 2007. **50**(3): p. 585-95.
325. Dotti, C.G., R.G. Parton, and K. Simons, *Polarized sorting of glypiated proteins in hippocampal neurons*. Nature, 1991. **349**(6305): p. 158-61.
326. Matas-Rico, E., M. van Veen, and W.H. Moolenaar, *Neuronal differentiation through GPI-anchor cleavage*. Cell Cycle, 2017. **16**(5): p. 388-389.

